查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771576

性行為感染分子診斷市場規模、佔有率、趨勢分析報告：按產品、應用、技術、地區、細分市場預測，2025-2033

Molecular Diagnostics For STD Market Size, Share & Trends Analysis Report By Product, By Application, By Technology, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

性行為感染傳染病分子診斷市場摘要

2024 年全球性行為感染傳染病 (STD) 分子診斷市場規模估計為 33.6 億美元，預計到 2030 年將達到 69.4 億美元，2025 年至 2033 年期間的複合年成長率為 8.35%。披衣菌感染、淋病、梅毒和人類乳突病毒 (HPV) 等性行為感染傳染病的盛行率不斷上升是推動市場成長的關鍵因素。

精準早期檢測的需求推動了分子診斷工具的普及。核酸擴增技術的進步以及人們對定期性傳染病（STD）篩檢的日益重視也推動了市場擴張。為了順應這一趨勢，診斷開發人員正專注於下一代分子檢測，以實現對性行為感染疾病病原體的快速、多重和高通量檢測。最近的創新包括照護現場核酸增幅檢查和基於PCR的可攜式設備，旨在在最短時間內提供準確的結果。例如，2025年3月，Visby Medical公司的女性性健康檢測產品獲得了美國食品藥物管理局（FDA）的從頭許可，這是第一個核准用於家庭使用的商用PCR診斷設備。這款手掌大小的設備能夠快速可靠地檢測披衣菌感染、淋病和滴蟲病，30分鐘內即可得出結果，無需實驗室處理。這些進步反映了市場對擴大可靠檢測管道、縮短診斷週轉時間以及透過早期精準檢測加強患者管理的關注。

此外，分子診斷研究的技術進步促進了更靈敏、更特異性傳染感染（性行為感染）檢測方法的發展。檢測設計、樣本處理和擴增技術的創新提高了診斷準確性，並減少了假陰性，這對於有效的疾病管理至關重要。這些進步有助於應對檢測無症狀性感染和合併感染方面的現有挑戰，尤其是在高風險族群中。此外，診斷設備製造商和公共衛生機構持續的研究投入正在幫助拓展分子診斷產品線，並促進其在各種醫療保健環境中的更廣泛應用。

儘管性傳染病分子診斷市場不斷取得進展，但仍面臨許多挑戰，這些挑戰可能會限制其成長。新型分子診斷檢測的開發、檢驗和監管核准需要大量的時間和資源，製造商必須遵守嚴格的安全和性能標準。這些因素可能會延遲產品上市並限制市場供應。此外，確保持續獲得診斷技術在後勤方面也極具挑戰性，尤其是在醫療基礎設施有限的地區。可靠的樣本儲存、運輸和熟練的人員配置使得在偏遠和服務欠缺地區進行檢測變得複雜。這些挑戰凸顯了我們需要齊心協力，克服監管障礙，改善分銷網路，以在全球範圍內擴大性傳染病分子診斷的可及性。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章性行為感染傳染病（STD）分子診斷市場的變數、趨勢與範圍

  • 市場介紹/電網展望
  • 市場規模和成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 性行為感染傳染病（STD）分子診斷市場的分析工具
    • 波特分析
    • PESTEL分析

第4章。性行為感染傳染病（STD）分子診斷市場：按產品的估計和趨勢分析

  • 細分儀表板
  • 性行為感染傳染病（STD）分子診斷市場：2024 年及 2033 年各產品差異分析
  • 設備和服務
  • 耗材（試劑和套件）
  • 軟體

第5章。性行為感染傳染病（STD）分子診斷市場：按應用的估計和趨勢分析

  • 細分儀表板
  • 性行為感染傳染病（STD）分子診斷市場：2024 年和 2033 年應用趨勢分析
  • CT/NG檢查
  • 梅毒檢測
  • 淋病檢測
  • HSV偵測
  • HPV檢測
  • HIV檢測
  • 滴蟲
  • 脲原體+黴漿菌
  • 其他

第6章。性行為感染傳染病（STD）分子診斷市場：按技術進行的估計和趨勢分析

  • 細分儀表板
  • 性行為感染傳染病 (STD) 分子診斷市場：2024 年和 2033 年技術趨勢分析
  • 實驗室測試
    • 商業/私人實驗室
    • 公共衛生研究所
  • PoC 測試

第7章。性行為感染傳染病（STD）分子診斷市場：按地區估計和趨勢分析

  • 2024年及2033年各地區性行為感染傳染病（STD）分子診斷市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
    • BD
    • F. Hoffmann-La Roche Ltd
    • Hologic Inc.
    • Abbott
    • Cepheid（Danaher）
    • Qiagen
    • OraSure Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Thermo Fisher Scientific, Inc.
    • Seegene Inc.
    • DiaSorin SpA
Product Code: GVR-4-68040-619-4

Molecular Diagnostics For STD Market Summary

The global molecular diagnostics for sexually transmitted diseases (STDs) market size was estimated at USD 3.36 billion in 2024 and is projected to reach USD 6.94 billion by 2030, growing at a CAGR of 8.35% from 2025 to 2033. The increasing incidence of sexually transmitted infections such as chlamydia, gonorrhea, syphilis, and human papillomavirus (HPV) is a key factor driving market growth.

The demand for accurate and early detection contributes to the uptake of molecular diagnostic tools. Improvements in nucleic acid amplification technologies and growing awareness about regular STD screening are also supporting market expansion. Supporting this trend, diagnostic developers are concentrating on next-generation molecular tests that offer rapid, multiplexed, and high-throughput detection of sexually transmitted pathogens. Recent innovations include point-of-care nucleic acid amplification tests and portable PCR-based devices designed to deliver accurate results in minimal time. For instance, in March 2025, Visby Medical received U.S. Food and Drug Administration (FDA) De Novo authorization for its Women's Sexual Health Test, the first over-the-counter PCR diagnostic device approved for at-home use. This palm-sized device enables rapid, reliable testing for chlamydia, gonorrhea, and trichomoniasis, providing results within 30 minutes without needing laboratory processing. Such advancements reflect the market's focus on expanding access to reliable testing, reducing diagnostic turnaround time, and enhancing patient management through early and precise detection.

Moreover, technological progress in molecular diagnostic research has enabled the development of more sensitive, specific, and targeted tests for sexually transmitted infections. Innovations in assay design, sample processing, and amplification techniques have improved diagnostic accuracy and reduced false negatives, crucial for effective disease management. These advancements help address existing challenges in detecting asymptomatic infections and co-infections, especially in high-risk populations. In addition, continued investment in research by diagnostic manufacturers and public health organizations supports the expansion of molecular diagnostics pipelines and promotes wider availability across diverse healthcare settings.

Despite ongoing progress, the molecular diagnostics for STD market faces several challenges that may limit growth. The development, validation, and regulatory approval of new molecular tests require substantial time and resources, with manufacturers needing to comply with rigorous safety and performance standards. These factors often cause delays in product launches and restrict market availability. In addition, ensuring consistent access to diagnostic technologies presents logistical difficulties, especially in regions with limited healthcare infrastructure. The need for reliable sample storage, transportation, and skilled personnel complicates test deployment in remote or underserved areas. These challenges highlight the necessity for coordinated efforts to address regulatory hurdles and improve distribution networks to expand access to molecular diagnostics for STDs worldwide.

Global Molecular Diagnostics For STDs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global molecular diagnostics for sexually transmitted diseases (STDs) market report based on product, application, technology, and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments & Services
  • Consumables (Reagents and kits)
  • Softwares
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • CT/NG Testing
  • Syphilis Testing
  • Gonorrhea Testing
  • HSV Testing
  • HPV Testing
  • HIV Testing
  • Trichomonas
  • Ureaplasma + Mycoplasma
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Laboratory Testing
    • Commercial/Private Labs
    • Public Health Labs
  • PoC testing
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Movement Analysis, 2024 & 2033 (USD Million)
  • 4.3. Instruments & Services
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Consumables (Reagents and kits)
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Software
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Movement Analysis, 2024 & 2033 (USD Million)
  • 5.3. CT/NG testing
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Syphilis testing
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Gonorrhea testing
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. HSV testing
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. HPV testing
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. HIV testing
    • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Trichomonas
    • 5.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.10. Ureaplasma + Mycoplasma
    • 5.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.11. Others
    • 5.11.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Movement Analysis, 2024 & 2033 (USD Million)
  • 6.3. Laboratory Testing
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Commercial/Private Labs
      • 6.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Public Health Labs
      • 6.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. PoC testing
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Regional Estimates & Trend Analysis

  • 7.1. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Share, By Region, 2024 & 2033, USD Million
  • 7.2. North America
    • 7.2.1. North America Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. South Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. BD
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. F. Hoffmann-La Roche Ltd
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Hologic Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Abbott
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Cepheid (Danaher)
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Qiagen
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. OraSure Technologies, Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Bio-Rad Laboratories, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. bioMerieux SA
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Thermo Fisher Scientific, Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Seegene Inc.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. DiaSorin S.p.A
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 5 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 6 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 7 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 9 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 10 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 11 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 12 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 13 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 14 Canada Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 15 Canada Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 16 Canada Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 17 Mexico Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 18 Mexico Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 20 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 22 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 23 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 24 Germany Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 25 Germany Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 26 Germany Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 27 UK Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 28 UK Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 29 UK Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 30 France Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 31 France Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 32 France Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 33 Italy Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 34 Italy Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 35 Italy Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 36 Spain Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 37 Spain Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 38 Spain Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 39 Denmark Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 40 Denmark Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 41 Denmark Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 42 Sweden Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 43 Sweden Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 44 Sweden Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 45 Norway Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 46 Norway Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 47 Norway Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 52 Japan Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 53 Japan Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 54 Japan Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 55 China Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 56 China Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 57 China Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 58 India Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 59 India Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 60 India Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 61 South Korea Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 62 South Korea Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 63 South Korea Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 64 Australia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 65 Australia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 66 Australia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 67 Thailand Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 68 Thailand Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 69 Thailand Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 70 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 72 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 73 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 74 Brazil Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 75 Brazil Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 76 Brazil Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 77 Argentina Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 78 Argentina Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 79 Argentina Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 86 Saudi Arabia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 87 South Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 88 South Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 89 South Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 90 UAE Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 91 UAE Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 92 UAE Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Product outlook key takeaways
  • Fig. 20 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Product movement analysis
  • Fig. 21 Instruments & Services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Consumables (Reagents and kits) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Softwares market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Application outlook key takeaways
  • Fig. 25 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Application movement analysis
  • Fig. 26 CT/NG testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Syphilis testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Gonorrhea testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 HSV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 HPV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 HIV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Trichomonas market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Ureaplasma + Mycoplasma market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Technology outlook key takeaways
  • Fig. 36 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Technology movement analysis
  • Fig. 37 Laboratory Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Commercial/Private Labs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Public Health Labs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 PoC testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Regional marketplace outlook, 2024 & 2033 (USD million)
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecasts, 2021 - 2033
  • Fig. 45 U.S.
  • Fig. 46 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 47 Canada
  • Fig. 48 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 49 Mexico
  • Fig. 50 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecasts, 2021 - 2033
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 57 France
  • Fig. 58 France market estimates and forecasts, 2021 - 2033
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 65 Sweden
  • Fig. 66 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 67 Norway
  • Fig. 68 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 71 China
  • Fig. 72 China market estimates and forecasts, 2021 - 2033
  • Fig. 73 Japan
  • Fig. 74 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 75 India
  • Fig. 76 India market estimates and forecasts, 2021 - 2033
  • Fig. 77 Thailand
  • Fig. 78 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 79 South Korea
  • Fig. 80 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 81 Australia
  • Fig. 82 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 85 Brazil
  • Fig. 86 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 87 Argentina
  • Fig. 88 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 89 Middle East and Africa
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 91 South Africa
  • Fig. 92 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 93 Saudi Arabia
  • Fig. 94 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 95 UAE
  • Fig. 96 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 97 Kuwait
  • Fig. 98 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 99 Market share of key market players-
  • Fig. 100 Market participant categorization
  • Fig. 101 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market position analysis, 2024
  • Fig. 102 Strategic framework